Metastatic Castration-Resistant Prostate Carcinoma
Conditions
Keywords
Prostate Cancer, 177Lu, PSMA, mCRPC, Radioligand Therapy
Brief summary
This study is being performed to establish the association between absorbed dose to tumor and response and absorbed dose to normal organs and toxicity following Lu177-PSMA radioligand therapy
Interventions
OTHERNon-Interventional Study
Non-interventional study
Sponsors
University of Michigan Rogel Cancer Center
National Cancer Institute (NCI)
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
MALE
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* \* 177Lu-617 PSMA treatment scheduled for mCRPC * Clinically stable as determined by the nuclear medicine clinicians * Male * ≥ 18 years of age * Willing and able to provide informed consent
Exclusion criteria
* Patients who are unable to lie flat on the imaging systems long enough to permit imaging protocols to be performed
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Response and toxicity following 177Lu-RLT | Up to 4 years | Association between absorbed dose and effect (response/toxicity) following 177Lu-RLT |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Build and test models | Up to 4 years | Build and test models for predicting therapy delivered absorbed dose from pre-therapy PET imaging/non-imaging biomarkers. |
Countries
United States
Contacts
PRINCIPAL_INVESTIGATORYuni K Dewaraja
University of Michigan Rogel Cancer Center
Outcome results
None listed